Home › Compare › GRGCF vs ABBV
GRGCF yields 4.49% · ABBV yields 3.12%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, GRGCF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GRGCF + ABBV for your $10,000?
Georgia Capital PLC is a private equity and venture capital firm specializing in early stage, organic growth and acquisitions. It consider greenfields through mature stage companies. The firm typically invests in automotive retail, education services, hotels, resorts & cruise lines, restaurants, beverages, healthcare, banks, property and casualty insurance, life and health insurance, advertising, diversified REITs, water utilities, and renewable electricity. It seeks to invest in Georgia. The firm seeks board position in public portfolio companies. It exits through IPO or trade sale in five to ten years. The firm raises capital through equity and debt market transactions. Georgia Capital PLC was founded in 2018 and is based in Tbilisi, Georgia with additional office in London, Greater London and Bristol, United Kingdom. Georgia Capital PLC operates independently of BGEO Group plc as of May 29, 2018.
Full GRGCF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.